Glucagon Like Peptide-1 (GLP-1)
Agonists Market
Glucagon Like Peptide-1 (GLP-1) Agonists Market
Scope: Industry Analysis, Market Size, Growth,
Trends Till 2031
Request Sample Report
Glucagon Like Peptide-1 (GLP-1) Agonists Market Size
and Growth
The global market for Glucagon Like Peptide-1 (GLP-1) Agonists is projected to experience significant growth due to the rising prevalence of diabetes and obesity. The market size for GLP-1 agonists is estimated to reach $9.2 billion by 2025, driven by increasing demand for effective treatments for Type 2 diabetes.
Request Sample Report
Companies Covered
(Covid 19 Impact Covered)
◍ Novo Nordisk
◍ GSK
◍ AstraZeneca
◍ Amylin
◍ Eli Lilly
◍ Bristol-Myers Squibb
◍ Sanofi
◍ ...
The GLP-1 agonists market is highly competitive with key players like Novo Nordisk, GSK, AstraZeneca, Amylin, Eli Lilly, Bristol-Myers Squibb, and Sanofi. These companies use GLP-1 agonists to develop innovative diabetes treatments, expand their product portfolios, and drive revenue growth. Sales revenue figures: Novo Nordisk$18.6 billion, AstraZeneca - $24.4 billion, Eli Lilly - $24.6 billion.
Market Segmentation
By Application
Hospital
Pharmacy
Other
Request Sample Report
By Product
Exenatied
Liraglutide
Lixisenatide
Albiglutide
Dulaglutide
Market Growth
Request Sample Report
$ X Billion USD
